2023 National Healthcare Reimbursement Negotiations to Kick Off in Beijing with Blockbuster Drug Lineup

Gelonghui November 16 | According to Lanjing Finance, learned from multiple sources that the 2023 National Medical Insurance Negotiation is expected to be held tomorrow (November 17) at the International Exchange Center of the All-China Federation of Trade Unions in Beijing. The varieties involved in this negotiation not only include many PD-1 products, such as Hengrui Pharma's Camrelizumab, INNOVENT BIO's Sintilimab, and BeOne Medicines' Tislelizumab, which are expected to participate in the new indication negotiations, but also the "second-time" "astronomically priced" CAR-T drugs — Fosun Kite Biotechnology Co., Ltd.'s Axicabtagene Ciloleucel Injection and JW Therapeutics' Relmacabtagene Autoleucel Injection.